Group 1 - The company, TeBao Bio, announced its participation in the 2025 semi-annual performance briefing for the biopharmaceutical and CXO industry on September 15, 2025, from 15:00 to 17:00 [2]

格隆汇9月5日丨特宝生物(688278.SH)公布，公司于2025年9月4日分别召开第九届董事会第十一次会议 和第九届监事会第八次会议，审议通过了《关于向2024年限制性股票激励计划激励对象授予预留部分限 制性股票的议案》，确定2025年9月4日为预留授予日，以39.18元/股的授予价格向372名激励对象授予 120.00万股。 ...

Group 1 - The core point of the article is that 特宝生物 (Tebao Biotech) held its 11th meeting of the 9th Board of Directors on September 4, 2025, to discuss the proposal for granting reserved restricted stocks under the 2024 restricted stock incentive plan [1] - For the year 2024, the revenue composition of 特宝生物 indicates that 99.73% comes from biopharmaceuticals, while other businesses account for only 0.27% [1] - As of the time of reporting, 特宝生物 has a market capitalization of 34.5 billion yuan [1] Group 2 - The article also mentions 海底捞 (Haidilao) and its various ventures, highlighting that the survival rate of its sub-brands is less than 50% [1]

Core Viewpoint - The company, Amoytop Biopharmaceuticals Co., Ltd., is holding a performance briefing on September 15, 2025, to discuss its 2025 semi-annual financial results and operational performance with investors [1][2]. Group 1: Meeting Details - The performance briefing is scheduled for September 15, 2025, from 15:00 to 17:00 [2][3]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3]. - Investors can submit questions from September 8 to September 12, 2025, through the Roadshow Center website or via the company's email [3]. Group 2: Participants - Key participants in the meeting will include the company's Chairman and General Manager, Mr. Sun Li, and the Vice General Manager and Financial Director, Ms. Yang Yiling, along with independent director Mr. Liu Qi [2]. Group 3: Investor Participation - Investors can participate in the performance briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [2][3]. - The company will address commonly asked questions during the briefing [2][3]. Group 4: Contact Information - For inquiries, investors can contact the Board Office at phone number 0592-6889118 or via email at ir@amoytop.com [3].

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng (Shenzhen) Law Firm addresses the adjustment of the grant price for the 2024 restricted stock incentive plan of Xiamen TeBao Biological Engineering Co., Ltd. and the granting of reserved restricted stocks to the incentive objects of the plan [1][2][3] Group 1: Adjustment of Grant Price - The grant price for the 2024 restricted stock incentive plan has been adjusted to 39.18 yuan per share from the previous price of 39.80 yuan per share due to a cash dividend distribution of 0.62 yuan per share [8][9][11] - The adjustment was approved by the company's board of directors and is in compliance with the relevant regulations of the Management Measures for Equity Incentives of Listed Companies and the company's incentive plan [7][10] Group 2: Reserved Stock Granting - The company plans to grant 1.2 million shares of restricted stock to 372 eligible incentive objects on September 4, 2025, at the adjusted price of 39.18 yuan per share [11][12] - The granting conditions for the reserved stocks have been met, and the company has fulfilled the necessary approval and authorization processes [10][12] Group 3: Compliance and Disclosure - The company has complied with the necessary legal and regulatory requirements for the adjustment and granting of the incentive plan, ensuring that all actions are in line with the applicable laws and regulations [10][12] - The company is required to continue fulfilling its information disclosure obligations as the incentive plan progresses [12]

上海荣正企业咨询服务（集团）股份有限公司 关于 厦门特宝生物工程股份有限公司 预留授予相关事项 之 证券简称：特宝生物 证券代码：688278 独立财务顾问报告 目 录 （二）本次实施的限制性股票激励计划与股东大会审议通过的限制性股票激 一、释义 生物工程股份有限公司 2024 年限制性股票激励计划（草案）》。 满足相应的归属条件后分次获得并登记的本公司 A 股普通股股票。 员、核心技术人员以及公司董事会认为需要激励的其他员工。 作废失效的期间 为。 足的获益条件。 必须为交易日。 息披露》 二、声明 本独立财务顾问对本报告特作如下声明： （一）本独立财务顾问报告所依据的文件、材料由特宝生物提供，本激励 计划所涉及的各方已向独立财务顾问保证：所提供的出具本独立财务顾问报告 所依据的所有文件和材料合法、真实、准确、完整、及时，不存在任何遗漏、 虚假或误导性陈述，并对其合法性、真实性、准确性、完整性、及时性负责。 本独立财务顾问不承担由此引起的任何风险责任。 （二）本独立财务顾问仅就本次限制性股票激励计划预留授予相关事项对 特宝生物股东是否公平、合理，对股东的权益和上市公司持续经营的影响发表 意见，不构成对公司的 ...

Core Viewpoint - The incentive plan of Xiamen Tebao Biological Engineering Co., Ltd. involves the allocation of restricted stocks to 372 individuals, with a total of 1.2 million shares reserved for distribution, representing 0.29% of the total share capital at the time of the plan's submission to the shareholders' meeting [1] Group 1 - The total number of restricted stocks granted to the incentive recipients is 1.2 million shares [1] - The reserved shares account for 100% of the total reserved grant of restricted stocks [1] - The total number of shares involved in the incentive plan does not exceed 1% of the company's total share capital at the time of the plan's submission [1]

Core Viewpoint - The company has adjusted the grant price of the 2024 restricted stock incentive plan from 39.80 CNY per share to 39.18 CNY per share due to the implementation of the annual profit distribution plan [5][6][7]. Group 1: Decision-Making Process - The board of directors and the supervisory board approved the adjustment of the grant price during their respective meetings held on September 4, 2025 [1][5]. - The adjustment follows the procedures outlined in the company's 2024 restricted stock incentive plan draft and was authorized by the shareholders at the first extraordinary general meeting of 2024 [2][3]. Group 2: Adjustment Details - The adjustment was made based on the profit distribution plan approved at the 2024 annual general meeting, which included a cash dividend of 0.62 CNY per share [6]. - The formula used for the adjustment is P = P0 - V, where P0 is the original grant price, V is the cash dividend per share, and P is the adjusted grant price [6]. Group 3: Impact of Adjustment - The adjustment of the grant price is a result of the annual profit distribution and will not have a substantial impact on the company's financial status or operating results [6][7]. - The supervisory board confirmed that the adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [7]. Group 4: Legal Opinions - The company has obtained necessary approvals for the adjustment, ensuring compliance with relevant regulations and guidelines [7][8]. - The conditions for the reserved portion of the incentive plan have been met, and the company will continue to fulfill its information disclosure obligations as the incentive plan progresses [8].

Core Viewpoint - The Supervisory Board of Xiamen Tebao Biological Engineering Co., Ltd. has reviewed and approved the list of incentive recipients for the 2024 restricted stock incentive plan, confirming compliance with relevant laws and regulations [1][2]. Group 1: Compliance and Eligibility - All proposed incentive recipients meet the eligibility criteria outlined in the Management Measures, with no disqualifying conditions present [1]. - The list of incentive recipients excludes independent directors, supervisors, foreign employees, shareholders holding more than 5% of the company's shares, and immediate family members of the actual controller [2]. - The incentive recipients align with the scope defined in the draft of the 2024 restricted stock incentive plan approved by the company's first extraordinary general meeting of shareholders [2]. Group 2: Plan Details - The Supervisory Board has agreed to set September 4, 2025, as the date for the reserved grant of the incentive plan, with a grant price of 39.18 yuan per share for 1.2 million restricted shares to 372 recipients [2].

证券代码：688278 证券简称：特宝生物 公告编号：2025- 厦门特宝生物工程股份有限公司 关于向 2024 年限制性股票激励计划激励对象 授予预留部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ? 限 制 性 股 票 预 留 授 予 数 量 ： 120.00 万 股 ， 占 目 前 公 司 股 本 总 额 重要内容提示： ? 股权激励方式：第二类限制性股票 ? 限制性股票预留授予日：2025 年 9 月 4 日 厦门特宝生物工程股份有限公司（以下简称"公司"）《2024 年限制性股 票激励计划（草案）》（以下简称"《激励计划（草案）》"或"本激励计划"） 规定的限制性股票授予条件已经成就，根据公司 2024 年第一次临时股东大会的 授权，公司于 2025 年 9 月 4 日分别召开第九届董事会第十一次会议和第九届监 事会第八次会议，审议通过了《关于向 2024 年限制性股票激励计划激励对象授 予预留部分限制性股票的议案》，确定 2025 年 9 月 4 日为预留授予日，以 39.18 元/股的授 ...